Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Ivacaftor(VX-770)
Cat No.
CEI-0251
Description
VX-770 is an orally bioavailable CFTR potentiator and VX-770 is in clinical development for the treatment of Cystic fibrosis.
CAS No.
873054-44-5
Molecular Weight
392.49
Purity
>99%
Storage
2 years at -20centigrade Powder
Targets
G551D-CFTR, F508del-CFTR
Molecular Formula
C24H28N2O3
Chemical Name
N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
Solubility
DMSO 79 mg/mL Water
In vitro
VX-770 is an orally bioavailable CFTR potentiator and VX-770 is in clinical development for the treatment of Cystic fibrosis. VX-770 bound directly to the CFTR protein, rather than associated kinases or phosphatases. VX-770 can cause CFTR channel opening through a non-conventional, ATP-independent mechanism. In recombinant cells VX-770 increased CFTR channel open probability (P(o)) in both the F508del processing mutation and the G551D gating mutation. VX-770 also increased Cl(-) secretion in cultured human CF bronchial epithelia (HBE) carrying the G551D gating mutation on one allele and the F508del processing mutation on the other allele by approximately 10-fold, to approximately 50% of that observed in HBE isolated from individuals without CF. VX-770 reduces excessive Na(+) and fluid absorption to prevent dehydration of the apical surface and increased cilia beating in these epithelial cultures.
Download
Download Datasheet